Quick answer: There is no evidence-based "top three" vitamins for menopause. No clinical guideline ranks them that way, and the two nutrients that health bodies do name during the transition β calcium and vitamin D β are named for bone, not for symptoms. The herbal supplements sold for hot flashes are a separate question with a blunter answer: The Menopause Society's 2023 review worked through fifteen of them and recommended none.
"Perimenopause supplements" is really two aisles side by side, and most pages collapse them into one. The first holds nutrients with a measurable rationale for this life stage. The second holds botanicals sold to fix a symptom, most of which have been tested and have not beaten placebo.
Is there a "top 3" for menopause?
No, and the gap between the question and the evidence is easy to show.
Three bodies that publish menopause guidance for the public name the same two nutrients, and each of them names them under bone health. The NHS tells women in perimenopause to "eat a healthy diet that includes plenty of fruit, vegetables and sources of calcium, such as milk, yoghurt and kale," and to "take vitamin D supplements" (NHS, page last reviewed 19 May 2026). The National Institute on Aging says that after menopause "it is important to continue to eat a healthy diet, stay active, and get enough calcium and vitamin D for optimal bone health" (NIA). ACOG puts the emphasis on food: "Be sure to include enough calcium and vitamin D in your diet to help maintain strong bones" (ACOG FAQ047, last reviewed December 2025). None of them ranks anything, and none names a third nutrient.
Here is the part that settles it. The Menopause Society's 2023 nonhormone therapy position statement is the document that grades supplements for hot flashes and night sweats, one by one, with an evidence level attached. Search it for calcium, or for vitamin D, and you get nothing (The Menopause Society, 2023). That is not an oversight. It is scope: the statement is about vasomotor symptoms, and calcium and vitamin D are not symptom treatments. The two nutrients with the best claim on your attention in this window are missing from the one guideline that grades supplements, because they answer a different question.
So the honest short list has two items on it, and neither is for hot flashes. The names that fill out a "top 3" on product pages β vitamin D again, magnesium, a B-complex, vitamin E β are covered further down, each in the place its evidence actually sits.
Calcium and vitamin D: the two with a reason specific to this window
Bone is the reason, and the timing is specific. SWAN, the Study of Women's Health Across the Nation, tracked bone mineral density in 862 women over ten years. Lumbar spine density fell 10.6% in total β but 7.38% of that went during what the researchers called the transmenopause, from one year before the final period to two years after it. The femoral neck followed the same shape: 9.1% overall, 5.8% inside that window (Greendale et al., 2012).
Three years accounting for most of a decade's loss is what turns calcium and vitamin D from generic good advice into something worth checking now. That window straddles the end of perimenopause rather than sitting after it: under the STRAW+10 criteria the transition ends 12 months after the final period, so the first postmenopausal year is still inside it (Harlow et al., 2012) β explained in what perimenopause actually is. ACOG describes the same pattern from the other side: "during the first 4-8 years after menopause, women lose bone more rapidly."
How much, and why the UK and US numbers don't match
| UK reference intake (NHS) | US reference intake (Institute of Medicine, 2011) | |
|---|---|---|
| Calcium | 700 mg a day for adults aged 19 to 64 | 1,000 mg a day at 19-50; 1,200 mg a day for women 51-70 |
| Vitamin D | 10 micrograms (400 IU) a day. From late March to the end of September most people make what they need from sunlight; through autumn and winter "everyone β¦ should consider taking a daily supplement containing 10 micrograms" | 600 IU (15 mcg) a day to age 70, rising to 800 IU (20 mcg) from 71 |
| Stated upper limits | "Do not take more than 100 micrograms (4,000 IU) of vitamin D a day"; more than 1,500 mg of calcium a day "could lead to stomach pain and diarrhoea" | 4,000 IU a day of vitamin D; 2,500 mg a day of calcium to age 50, 2,000 mg a day from 51 |
UK figures from NHS calcium and vitamin D (both pages last reviewed 3 August 2020). US figures are the Institute of Medicine's 2011 Dietary Reference Intakes, reported in Ross et al., 2011 and listed on MedlinePlus.
The UK calcium figure is a little over half the American one for a woman in her fifties, and the UK vitamin D figure is two-thirds of it. One thing that is documented about the US numbers: the committee set them "based on an assumption of minimal or no sun exposure," which it justified by the variability of synthesis from ultraviolet light and the risks of skin cancer (Ross et al., 2011). Beyond that, these are two national reference intakes set by separate processes, and neither the NHS pages nor the IOM summary addresses the other's figure. The practical answer is to work from the one your own clinician uses.
A genuine disagreement sits inside the US numbers too. The Bone Health and Osteoporosis Foundation recommends 800 to 1,000 IU of vitamin D daily for people aged 50 and older, above the reference intake, which MedlinePlus notes alongside the official figure (MedlinePlus).
Adequacy is one question; taking a supplement is another
This is where the supplement pages we read stopped, and it is the part that changes what you would actually do. Meeting the intake is well supported. Adding a supplement on top of an adequate diet, on spec, is not.
The US Preventive Services Task Force "recommends against daily supplementation with 400 IU or less of vitamin D and 1000 mg or less of calcium for the primary prevention of fractures in community-dwelling, postmenopausal women" (USPSTF, final recommendation 17 April 2018). The main reason is the Women's Health Initiative trial: 36,282 women took 400 IU of vitamin D3 with 1,000 mg of calcium or placebo, and the trial "reported no significant reduction in any fracture outcome." For higher doses the Task Force concluded that the evidence is insufficient either way. Two things travel with that recommendation. It excludes anyone with "a history of osteoporotic fractures, increased risk for falls, or a diagnosis of osteoporosis or vitamin D deficiency." And the Task Force's own page states that the topic is being updated, with a draft out for the wider question of falls and fractures, so the 2018 wording is current but not settled.
The Endocrine Society reached a similar place for vitamin D on its own. Its 2024 guideline "suggests against empiric vitamin D supplementation above the current DRI to lower the risk of disease in healthy adults younger than 75 years," where "empiric" means a dose above the reference intake taken without a blood test. The same panel "suggests against routine 25(OH)D testing" in the populations it looked at, and says explicitly that its recommendations "are not meant to replace the current DRIs for vitamin D" (Demay et al., 2024).
Read together, those two documents say something narrower than "don't bother." Reaching the reference intake matters. Testing a healthy person's vitamin D and then topping them up above it has not been shown to prevent disease, and low-dose combined supplements did not prevent fractures in women who were not already at raised risk. If you have osteoporosis, have broken a bone easily, or have been told you are vitamin D deficient, none of that applies to you β that is a treatment decision, and it belongs with a clinician.
That brings it back to food, and to how a dose actually behaves. Calcium absorption "is best when taken in amounts of no more than 500 mg at a time," so a single 1,000 mg tablet is not the same as 1,000 mg spread across a day. Calcium citrate "is taken up well by the body on a full or empty stomach," which matters if you take acid-reducing medication; calcium carbonate is cheaper and "is absorbed better by the body if taken with food." On the food side, an 8-ounce glass of nonfat milk, 1.5 ounces of cheese and 6 ounces of yoghurt each supply about 300 mg of calcium, and 3 ounces of sardines with bones 325 mg (all from MedlinePlus, review date 21 January 2025). That is how a supplement earns its place: it closes a measured gap rather than adding insurance on top of a diet that already works. The food side is covered in our guide to eating during perimenopause.
Vitamin E, magnesium and B12
These three turn up more than anything else on the supplement pages we read while researching this guide, and the evidence for each one sits somewhere different. One has been tested and graded. One has been tested but never graded. The third barely appears in a menopause context at all.
Vitamin E: tested, and not recommended
The Menopause Society went through the trials and concluded that "vitamin E is not recommended for the management of VMS. (Level I; not recommended)." What the panel had to work with: two crossover trials, of 120 and 50 women, that "showed limited reduction in VMS frequency with vitamin E compared with placebo," plus a 93-participant trial from Iran in which vitamin E separated from placebo at eight weeks, with sample sizes the panel called small enough to limit conclusions.
NCCIH is the more generous reading of the same literature, and it is still not an endorsement: "A few studies have suggested that vitamin E supplements might be helpful for menopause symptoms. However, the amount of research is small, and the effect is also small. For example, in one study, women taking vitamin E averaged one fewer hot flash per day" (NCCIH, last updated May 2017). Set that one-flash-a-day figure against the panel's own note that trials of non-hormone treatments for hot flashes carry "a placebo improvement rate of 20% to 66%," and the effect stops looking like much.
There is a safety line here that product pages rarely carry. Vitamin E "in the high doses found in supplements, may increase the risk of bleeding (including strokes due to bleeding in the brain) and interact with anticoagulant (blood-thinning) medications such as warfarin (Coumadin)" (NCCIH). If you take an anticoagulant, this is a conversation with your prescriber before anything else.
Magnesium: one good trial, and it was negative
The largest placebo-controlled trial of magnesium for hot flashes is North Central Cancer Treatment Group trial N10C2, run through the Alliance network. It randomised 289 women to magnesium oxide at 800 or 1,200 mg a day or to a matching placebo, in four arms, and measured hot flashes with a validated diary. The result: "Mean hot flash scores, mean hot flash frequencies, and associated changes during the treatment period were similar for each group." The authors' conclusion is one sentence long: "The results of this trial do not support the use of magnesium oxide for hot flashes." Diarrhoea was more common on magnesium, and constipation less so (Park et al., 2015).
Two limits belong with that, because they are the reason it is not the last word. Every participant was postmenopausal with a history of breast cancer, so this was not a perimenopausal sample. And it tested magnesium oxide, not the glycinate or citrate forms people also ask about.
One more thing, because it cuts both ways: magnesium is not on The Menopause Society's not-recommended list. It is not on any list. The word does not appear in the 2023 statement, in NICE's menopause guideline, in the NHS menopause pages, in ACOG's menopause FAQ, in the NIA or Office on Women's Health menopause pages, or in NCCIH's review of complementary approaches to menopause symptoms. That is an absence of assessment, not a verdict. It means a single trial in a different population is most of what exists, and that anyone telling you magnesium has been "shown" to reduce hot flashes is going further than the evidence goes.
Vitamin B12: no menopause-specific recommendation exists
We looked for one in the same seven sources, and vitamin B12 appears in none of them. There is no menopause-specific intake, no graded verdict, no guideline sentence to quote in either direction.
What that leaves is ordinary clinical ground rather than a menopause question. The NHS lists "extreme tiredness" and "a lack of energy" among the effects of a B12 or folate deficiency, and says such a deficiency "can often be diagnosed based on your symptoms and the results of a blood test" (NHS, page last reviewed 20 February 2023). It also gives the reason this matters more than most supplement questions: although many symptoms improve with treatment, "some problems caused by the condition can be irreversible," which is an argument for getting a diagnosis rather than covering the symptom with a bottle. If fatigue is what you are actually trying to treat, that is the step worth taking.
Black cohosh: the most-bought, and the most-studied
Black cohosh is, in the position statement's own words, "the most purchased botanical for menopause symptoms." It is also one of the most tested, and credible assessments still land in different places, which is why you will find confident claims in both directions. We go through the trial-by-trial detail, the European regulatory position and the liver question in a full review of the black cohosh evidence; the short version is below.

The strictest assessment is a September 2012 Cochrane review by Leach and Moore, pooling 16 randomised trials of 2,027 perimenopausal and postmenopausal women at a median of 40 mg a day over a mean of 23 weeks. For hot-flush frequency, the outcome most women care about, only three of those trials could be pooled, covering 393 women, and they gave a mean difference of 0.07 flushes per day against placebo, confidence interval β0.43 to 0.56, straddling zero. The authors' conclusion was that there is "currently insufficient evidence to support the use of black cohosh for menopausal symptoms" (Leach & Moore, 2012). The Menopause Society arrives at the same sentence β "there is insufficient evidence to support the use of black cohosh for VMS" β and does not recommend it (The Menopause Society, 2023). Neither is a finding that black cohosh does nothing. Both are findings that the trials cannot show it does something.
Two credible bodies read that evidence differently, and it is worth seeing the disagreement in their own words rather than averaging it:
- NICE, for the NHS in England, tells clinicians to "explain to people that there is some evidence that isoflavones or black cohosh may relieve vasomotor symptoms associated with menopause," while also explaining that "multiple preparations are available, and their safety is uncertain," that "different preparations may vary," and that "interactions with other medicines have been reported" (NICE NG23, 1.4.7). That recommendation carries a 2015 date stamp inside a guideline last updated on 15 April 2026, so its wording predates the guideline's more recent revisions.
- NCCIH points to a 2023 review of 22 studies of black cohosh products, alone or combined with other herbs, that found them "potentially beneficial for overall menopause symptoms," with improvements in hot flashes but not in anxiety or depressive symptoms (NCCIH).
So why do serious reviews land in different places on the same plant? Three documented reasons:
- The trials are hard to compare. Cochrane's own assessment was that "the quality of included trials was generally unclear, owing to inadequate reporting." Doses and extract types varied, and the newer review NCCIH cites included products combining black cohosh with other herbs, so the two are not weighing the same thing.
- Nobody knows what the active ingredient is. The position statement is blunt: "The active ingredients in black cohosh extract are unknown, and its mechanism of action is unclear." It was once thought oestrogenic; other work suggests activity resembling a selective oestrogen-receptor modulator, or an effect on serotonergic pathways. Without a mechanism there is no way to standardise what is tested.
- The reputation predates the trials. Black cohosh has been used medicinally in Germany since the late 19th century, and by Native Americans before that (NCCIH). More than a century of use built a reputation, and reference works from that period still circulate. Traditional use is a good reason to study a plant, not a substitute for the result.
Then the part supplement listicles rarely carry. Reports of possible liver toxicity began appearing after 2000. The US Pharmacopeial Convention's Dietary Supplements-Botanicals Expert Committee examined all reported cases, found 30 possibly related to black cohosh, and directed that products carry this warning:
"Discontinue use and consult a healthcare practitioner if you have a liver disorder or develop symptoms of liver trouble, such as abdominal pain, dark urine, or jaundice."
Hold NCCIH's framing alongside it: black cohosh has been used safely in studies lasting as long as a year and is generally well tolerated, the reported liver injuries are rare, and it is uncertain whether black cohosh caused them. The warning exists because those cases were serious enough to act on, not because the risk is common. NCCIH separately notes it is uncertain whether black cohosh is safe for women who have had a hormone-sensitive condition such as breast or uterine cancer.
Soy, isoflavones and equol
Soy foods, soy extracts and the soy metabolite equol all sit on the not-recommended list for vasomotor symptoms at Level II β limited or inconsistent evidence. The mechanism explains the inconsistency better than the verdict does.
The compound that binds oestrogen receptors is not the isoflavone you eat. It is equol, which your gut bacteria may or may not produce from the soy isoflavone daidzein, and "only 35% of North American women can metabolize the soy isoflavone daidzein to equol." In the study behind that figure, 129 of 365 women were equol producers; among them, the highest quartile of dietary daidzein intake was associated with 76% lower odds of above-average hot flash frequency (odds ratio 0.24, 95% CI 0.07-0.83), while among non-producers there was no association (Newton et al., 2015). Average an effect only a third of women can experience across a whole trial population and you get the mixed results the literature shows.
Then the dead end, in the position statement's next sentence: tests for equol-producer status "are not commercially available to the public or healthcare professionals." Even if the mechanism is real, neither you nor your doctor can find out whether it applies to you.
None of which is a safety finding. Soy is an ordinary food with separate, better-measured effects on blood cholesterol, which our diet guide covers alongside the rest of what you eat in this window.
The rest of the supplement aisle
Fifteen items sit under the statement's dietary-supplement headings, and none of them is recommended for vasomotor symptoms. Eight of them are in the table below; the other seven are soy foods and soy extracts, the soy metabolite equol, pollen extract, Siberian rhubarb, Labisia pumila/Eurycoma longifolia, milk thistle and omega-3s.
How to read the grade. The level describes the evidence the panel had in front of it, not the size of any benefit. In the statement's own definitions: "Level I: Good and consistent scientific evidence. Level II: Limited or inconsistent scientific evidence. Level III: Consensus and expert opinion." The recommendation is a separate judgement, which is why "Level I β not recommended" is so easy to misread: it does not mean the evidence is good for the supplement. It also does not mean the same thing in every row. For black cohosh the panel's conclusion is that "there is insufficient evidence to support the use of black cohosh for VMS," while for ginseng it is that ginseng "does not appear to be beneficial for VMS." Both carry Level I. The first says the trials cannot answer the question. The second says they answered it, and the answer was no.
| Supplement | Commonly sold for | What the review found | Grade (vasomotor symptoms) |
|---|---|---|---|
| Black cohosh | Hot flashes | 2012 Cochrane review, 16 trials, 2,027 women: no significant difference from placebo in hot flush frequency; "insufficient evidence to support the use" | Level I β not recommended |
| Wild yam cream | "Natural progesterone" | Diosgenin converts to progesterone in a test tube, but "there is no biochemical pathway for this conversion in vivo." Tested creams often contain no yam extract, and many have been adulterated with undisclosed steroids including oestrogens, progesterone and medroxyprogesterone acetate | Level II β not recommended |
| Dong quai | Hot flashes | Trial of 71 women, 4.5 g/day for 24 weeks: no difference on any measure, from hot flash frequency and symptom scores to FSH, LH and oestradiol. Safety concerns include photosensitisation, anticoagulation and carcinogenicity | Level II β not recommended |
| Evening primrose oil | Hot flashes | Single trial, 56 women, 500 mg/day for 6 months: hot flashes fell 1.0 a day on evening primrose oil and 2.6 a day on placebo | Level II β not recommended |
| Vitamin E | Hot flashes | Two crossover trials (120 and 50 women) showed only limited reduction versus placebo | Level I β not recommended |
| Ginseng | Hot flashes, energy | 384 postmenopausal women, 16 weeks: no greater reduction than placebo; two further studies found no effect | Level I β not recommended |
| Maca | Hot flashes, energy | Four studies showed symptom-score improvements, but quality, design, sample size and reporting limits mean "existing evidence is not strong enough" | Level II β not recommended |
| Chasteberry (Vitex) | Hot flashes | Four trials tested it inside mixed supplements, so "it is not possible to conclude that Vitex alone improves VMS" | Level II β not recommended |
All rows from The Menopause Society, 2023.
Read the evening primrose row again: in the only trial that exists, placebo did more than two and a half times as much as the supplement. That 20% to 66% placebo improvement rate is why uncontrolled testimonials are weak evidence, and why a supplement can feel like it is working without being what worked.
One botanical is absent because the panel did not assess it: ashwagandha appears nowhere in the 2023 statement. Two placebo-controlled trials in perimenopausal and menopausal women have measured it directly, and we go through them β limitations included β in ashwagandha for menopause, with a wider view in ashwagandha for women over 50. As with magnesium, absence from a guideline is not evidence in either direction.
Why supplement labels are a weak guarantee
Two findings here make the same point.

Wild yam creams were found adulterated with the very hormones a buyer choosing a plant-based cream is trying to avoid, and products labelled as black cohosh "have been found to contain the wrong herb or to contain mixtures of black cohosh and other herbs that are not listed on the label" β which NCCIH notes might possibly, though unprovenly, explain some of the liver injury cases.
The regulatory reason is checkable, and it is worth stating precisely. Responsibility for checking a supplement before it goes on sale sits with the company, not the regulator: US firms "are responsible for evaluating the safety and labeling of their products before marketing," and the agency's stated role comes afterwards, since the "FDA has the authority to take action against any adulterated or misbranded dietary supplement product" (FDA, content current as of 1 October 2024). NCCIH puts the consequence plainly: "What's on the label may not be what's in the product" (NCCIH, last updated January 2019).
The usual advice here is to look for a third-party quality mark, and the US Pharmacopeial Convention behind the black cohosh warning is a real standards body. But we could not verify, from any federal source we could open, how much a quality mark improves label accuracy β and the one direct statement we found cuts the other way: NCCIH says a manufacturer's use of "standardized," "verified" or "certified" "does not necessarily guarantee product quality or consistency." Preferring a verified product is reasonable. It is not a guarantee.
If you're going to take something anyway
Plenty of readers will, and a page that pretends otherwise is less useful. Four points, all from sources already cited:
- Tell your doctor and pharmacist what you take, herbal products included, and mention it well before any surgery. The interaction risk is not theoretical: dong quai's documented concerns include anticoagulation, vitamin E at supplement doses interacts with warfarin, and the FDA has found prescription drugs including anticoagulants and anticonvulsants in products sold as dietary supplements.
- If you take black cohosh, know the liver-warning symptoms quoted above β abdominal pain, dark urine, jaundice β plus the fatigue NCCIH adds, and treat them as a reason to stop and call someone.
- Pregnancy is still possible throughout perimenopause, even after missing periods for a month or several (Office on Women's Health) β and many supplements have never been tested in pregnancy. NCCIH notes black cohosh may not be safe during pregnancy or breastfeeding.
- A supplement that isn't working is worth stopping, not escalating. Given the size of the placebo response in hot flash trials, months of no clear change is information, and the answer is rarely a higher dose or a second bottle.
What the evidence does support
The same statement that recommends no supplement for hot flashes does recommend several other things, and the top of the list surprises most people. Cognitive behavioural therapy and clinical hypnosis are graded Level I β the same grade as SSRIs and SNRIs, gabapentin and fezolinetant. Oxybutynin sits at Levels I-II, weight loss and stellate ganglion block at Levels II-III.
One caveat travels with fezolinetant: it holds a Level I recommendation from the 2023 statement, and on 16 December 2024 the FDA added a boxed warning β its most prominent β for the known risk of rare but serious liver injury (FDA). The recommendation predates the warning, so the two belong together.
Be precise, finally, about what the not-recommended verdicts cover: vasomotor symptoms, and nothing else. They say nothing about bone, cardiovascular risk, mood, sleep or muscle, where the evidence for diet, exercise and nutrient adequacy is separate and much stronger β weight loss sitting on the recommended side of the same document makes the point. Our page on treatment options ranked by evidence works through the full list, what perimenopause symptoms are actually linked to it covers what you may be trying to treat, and body composition gets its own page.
Frequently asked questions about perimenopause supplements (FAQ)
What are the top 3 vitamins for menopause? There isn't one. No clinical guideline ranks vitamins for menopause, and the two nutrients that health bodies do name in this window β calcium and vitamin D β are named for bone, not for hot flashes. Reference intakes for women differ by country: 700 mg of calcium a day and 10 micrograms (400 IU) of vitamin D in the UK, against 1,200 mg of calcium from age 51 and 600 IU of vitamin D in the US. Food counts toward those totals first, and a supplement closes a gap a clinician has helped you identify.
Are perimenopause supplements safe? Safety cannot be read off the label. Responsibility for checking a supplement before it is sold sits with the company, not the regulator: US firms "are responsible for evaluating the safety and labeling of their products before marketing," and the FDA's stated role is to act against a product already adulterated or misbranded. Two documented consequences β tested wild yam creams often contain no yam extract and many have been adulterated with undisclosed steroids, and some products labelled as black cohosh contained the wrong herb. Tell your doctor and pharmacist about anything you take, since supplements can interact with prescribed medication.
Does black cohosh work for hot flashes? Reviews disagree, and so do guidelines. A 2012 Cochrane review of 16 randomised trials in 2,027 women found no significant difference from placebo in how often hot flushes occurred and concluded there was "insufficient evidence to support the use of black cohosh for menopausal symptoms." The Menopause Society reaches the same conclusion and does not recommend it; NICE, in England, tells clinicians to explain that "there is some evidence that isoflavones or black cohosh may relieve vasomotor symptoms," alongside warnings about uncertain safety and variable preparations. On safety, the US Pharmacopeial Convention's expert committee reviewed reports of possible liver injury and directed that black cohosh products carry this warning: "Discontinue use and consult a healthcare practitioner if you have a liver disorder or develop symptoms of liver trouble, such as abdominal pain, dark urine, or jaundice."
Does magnesium help with hot flashes? The largest placebo-controlled trial found no benefit. In North Central Cancer Treatment Group trial N10C2, 289 women took magnesium oxide 800 or 1,200 mg a day or a matching placebo; hot flash scores and frequencies "were similar for each group," and the authors concluded that "the results of this trial do not support the use of magnesium oxide for hot flashes." Diarrhoea was more common on magnesium. Two caveats: every participant was postmenopausal with a history of breast cancer, so this was not a perimenopausal sample, and only magnesium oxide was tested. Magnesium is not on The Menopause Society's not-recommended list because the panel did not assess it.
Does vitamin E help with hot flashes? Not to a degree that holds up. The Menopause Society reviewed the trials and concluded that "vitamin E is not recommended for the management of VMS. (Level I; not recommended)." NCCIH, which is more generous, still puts the effect at about "one fewer hot flash per day" in one study and notes that the amount of research is small. For context, trials of non-hormone treatments for hot flashes carry a placebo improvement rate of 20% to 66%. At supplement doses, vitamin E may also increase bleeding risk and interact with blood thinners such as warfarin.
What actually works for hot flashes if supplements don't? The Menopause Society's 2023 statement recommends cognitive behavioural therapy and clinical hypnosis at Level I, its highest evidence grade β the same grade it gives SSRIs and SNRIs, gabapentin and fezolinetant β plus oxybutynin at Levels I-II and weight loss at Levels II-III. Fezolinetant carries an FDA boxed warning for rare but serious liver injury, added on 16 December 2024. These are decisions for a healthcare provider, and our treatment guide sets out the full list.
Medical disclaimer: This article is for informational purposes only. Always consult a qualified healthcare provider before making changes to your health routine.
Sources
- The North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause 2023;30(6):573-590 β Clinical position statement (PDF). https://menopause.org/wp-content/uploads/professional/2023-nonhormone-therapy-position-statement.pdf
- Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD007244 β Systematic review. https://www.cochrane.org/evidence/CD007244_black-cohosh-cimicifuga-spp-menopausal-symptoms
- National Institute for Health and Care Excellence. Menopause: identification and management. NICE guideline NG23, published 12 November 2015, last updated 15 April 2026 β Clinical guideline (recommendation 1.4.7). https://www.nice.org.uk/guidance/ng23/chapter/Recommendations
- National Center for Complementary and Integrative Health (NIH). Black Cohosh β Federal research centre health topic page. https://www.nccih.nih.gov/health/black-cohosh
- National Center for Complementary and Integrative Health (NIH). Menopausal Symptoms: In Depth β Federal research centre review, last updated May 2017. https://www.nccih.nih.gov/health/menopausal-symptoms-in-depth
- National Center for Complementary and Integrative Health (NIH). Using Dietary Supplements Wisely β Federal research centre consumer guidance, last updated January 2019. https://www.nccih.nih.gov/health/using-dietary-supplements-wisely
- US Food and Drug Administration. Dietary Supplements β Federal regulator overview, content current as of 1 October 2024. https://www.fda.gov/food/dietary-supplements
- Greendale GA, Sowers M, Han W, et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN). Journal of Bone and Mineral Research 2012;27(1):111-118 β Peer-reviewed longitudinal cohort analysis. https://pubmed.ncbi.nlm.nih.gov/21976317/
- Newton KM, Reed SD, Uchiyama S, et al. A cross-sectional study of equol producer status and self-reported vasomotor symptoms. Menopause 2015;22(5):489-495 β Peer-reviewed observational study. https://pubmed.ncbi.nlm.nih.gov/25380274/
- Park H, Qin R, Smith TJ, et al. North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 2015;22(6):627-632 β Randomised placebo-controlled trial. https://pubmed.ncbi.nlm.nih.gov/25423327/
- Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. Journal of Clinical Endocrinology and Metabolism 2011;96(1):53-58 β Peer-reviewed summary of the IOM Dietary Reference Intakes. https://pmc.ncbi.nlm.nih.gov/articles/PMC3046611/
- Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2024;109(8):1907-1947 β Professional society clinical practice guideline. https://pubmed.ncbi.nlm.nih.gov/38828931/
- US Preventive Services Task Force. Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication β Final recommendation statement, 17 April 2018 (topic listed as being updated). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/vitamin-d-calcium-or-combined-supplementation-for-the-primary-prevention-of-fractures-in-adults-preventive-medication
- NHS. Calcium β Vitamins and minerals, page last reviewed 3 August 2020. https://www.nhs.uk/conditions/vitamins-and-minerals/calcium/
- NHS. Vitamin D β Vitamins and minerals, page last reviewed 3 August 2020. https://www.nhs.uk/conditions/vitamins-and-minerals/vitamin-d/
- NHS. Menopause and perimenopause: things you can do β page last reviewed 19 May 2026. https://www.nhs.uk/conditions/menopause-and-perimenopause/things-you-can-do/
- NHS. Vitamin B12 or folate deficiency anaemia β page last reviewed 20 February 2023. https://www.nhs.uk/conditions/vitamin-b12-or-folate-deficiency-anaemia/
- American College of Obstetricians and Gynecologists. The Menopause Years (FAQ047) β Patient guidance, published December 2018, last reviewed December 2025. https://www.acog.org/womens-health/faqs/the-menopause-years
- National Institute on Aging (NIH). What Is Menopause? β Government health information. https://www.nia.nih.gov/health/menopause/what-menopause
- MedlinePlus, US National Library of Medicine. Calcium in diet β Medical encyclopedia, review date 21 January 2025. https://medlineplus.gov/ency/article/002412.htm
- MedlinePlus, US National Library of Medicine. Vitamin D β Medical encyclopedia, review date 21 January 2025. https://medlineplus.gov/ency/article/002405.htm
- US Food and Drug Administration. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. Boxed Warning update 16 December 2024 β Federal regulator drug safety communication. https://www.fda.gov/drugs/drug-safety-communications/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due
- Office on Women's Health, US Department of Health and Human Services. Menopause basics β Government health information. https://womenshealth.gov/menopause/menopause-basics
- Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. 2012 β Consensus staging criteria, via PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC3340903/
Sources 1-2, 4, 8-9 and 20-24 were first accessed 4 August 2026; of those, sources 1-2, 8-9 and 20-21 were re-verified against the live source on 18 October 2026. Sources 3, 5-7 and 10-19 were accessed on 18 October 2026. Source 4 (the NCCIH black cohosh topic page) was not re-fetched on 18 October 2026; the same claims are sourced on our black cohosh review, re-verified 30 September 2026.




